{
    "clinical_study": {
        "@rank": "147901", 
        "acronym": "SPARTA", 
        "arm_group": [
            {
                "arm_group_label": "1.5 mcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks"
            }, 
            {
                "arm_group_label": "3.0 mcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks"
            }, 
            {
                "arm_group_label": "6.0 mcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks"
            }, 
            {
                "arm_group_label": "12.0 mcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks"
            }, 
            {
                "arm_group_label": "240 mcg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered via infusion once per week for 5 weeks"
            }, 
            {
                "arm_group_label": "420 mcg", 
                "arm_group_type": "Experimental", 
                "description": "PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of PRTX-100 when\n      various doses are given 5 times at weekly intervals to patients with active rheumatoid\n      arthritis that are taking methotrexate or leflunomide. The drug is administered in a\n      physician's office via an intravenous infusion.  PRTX-100 may be effective in rheumatoid\n      arthritis by suppressing the immune responses.\n\n      PRTX-100 is a highly-purified bacterial protein called Staphylococcal Protein A.  In this\n      study, cohorts of patients with active RA will receive sequentially higher doses of\n      PRTX-100.  There will be an inactive placebo cohort for comparison.  Patients who do not\n      attain low RA disease activity, by a commonly used measure, will leave the study at 3 months\n      after their first dose of study drug."
        }, 
        "brief_title": "Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Arthritis, Rheumatoid", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Active RA with disease duration of not less than 6 months\n\n          -  Concomitant stable methotrexate or leflunomide therapy\n\n        Exclusion Criteria:\n\n          -  Diagnosis of any other inflammatory arthritis\n\n          -  ACR Functional Classification of IV\n\n          -  Significant systemic involvement secondary to RA (except for secondary Sjogren's\n             syndrome)\n\n          -  History of clincally significant hypogammaglobulinemia, common variable\n             immunodeficiency, or humeral immunodeficientncy\n\n          -  History of active tuberculosis, pro-thrombotic disorder, venous thrombosis requiring\n             anti-coagulation, substance abuse, or serious psychiatric condition\n\n          -  History of allergy or hypersensitivity to aspirin or non-steroidal cyclooxygenase\n             inhibitors, Staphylococcal protein A\n\n          -  History or presence of malignancy (except for surgically treated basal or squamous\n             cell carcinoma of the skin at least 3 months prior to the start of study medication)\n\n          -  Uncontrolled diabetes or Type 1 diabetes\n\n          -  Unstable ischemic heart disease\n\n          -  Serious active or recurrent infection, hepatic cirrhosis, or other medically unstable\n             condition\n\n          -  Systemic autoimmune diseases other than RA (such as systemic lupus erythematosus,\n             scleroderma, inflammatory bowel disease, inflammatory myopathy)\n\n          -  Positive for HIV, hepatitis B surface antigen, or hepatitis C antibody\n\n          -  Pregnant or nursing females\n\n          -  Inadequate hepatic, renal, or hematologic function\n\n          -  Receipt of live vaccine within 5 weeks of start of study medication\n\n          -  Concomitant administration of other biologic or non-biologic DMARDS, corticosteroids,\n             or anti-CD20 antibodies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749787", 
            "org_study_id": "PRTX-100-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "1.5 mcg/kg", 
                "intervention_name": "PRTX-100 at 1.5 mcg/kg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }, 
            {
                "arm_group_label": "3.0 mcg/kg", 
                "intervention_name": "PRTX-100 at 3.0 mcg/kg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }, 
            {
                "arm_group_label": "6.0 mcg/kg", 
                "intervention_name": "PRTX-100 at 6.0 mcg/kg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }, 
            {
                "arm_group_label": "12.0 mcg/kg", 
                "intervention_name": "PRTX-100 at 12.0 mcg/kg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }, 
            {
                "arm_group_label": "240 mcg", 
                "intervention_name": "PRTX-100 at 240 mcg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered via infusion once per week for 5 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "420 mcg", 
                "intervention_name": "PRTX-100 at 420 mcg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Staphylococcal Protein A", 
                    "SpA"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Leflunomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "arthritis", 
            "rheumatoid", 
            "methotrexate", 
            "leflunomide"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Protalex Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34239"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coeur d'Alene", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83814"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anderson", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46011"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87102"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28144"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Allen", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75013"
                    }, 
                    "name": "Protalex Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "Protalex, Inc.", 
            "last_name": "William E Gannon, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "South Africa: Medicines Control Council"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number, severity and attribution of relatedness of Adverse Events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 53 Weeks"
            }, 
            {
                "description": "Change from baseline in blood pressure, heart rate, body temperature, and physical examination parameters", 
                "measure": "Vital Signs and Physical Examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 25 Weeks"
            }, 
            {
                "description": "Change from baseline in heart rate, PR interval, QT/QTc interval and QRS duration", 
                "measure": "ECG", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, first dose, 5th dose, 9 weeks, and 25 weeks"
            }, 
            {
                "description": "Change from baseline in blood chemistry, hematology, and urinalysis values", 
                "measure": "Clinical Laboratory Testing", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 25 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number and percentage of patients attaining an ACR20, ACR50 and ACR70 response at Week 13. Change from baseline in CDAI, RAPID 3, and DAS28-CRP scores.", 
                "measure": "Disease activity", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 53 weeks"
            }, 
            {
                "description": "Proportion of patients sero-positive and/or with titers > 512 at Week 4 and Week 9, the correlation between anti-product antibody and product clearance, and association between anti-product antibodies and adverse events.", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose, and at 4 weeks, 9 weeks,  and 25 weeks"
            }, 
            {
                "description": "Plasma Cmax, AUC0-n, clearance and Vd.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up to 72 hours after last dose of PRTX-100"
            }
        ], 
        "source": "Protalex, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protalex, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}